BridgeBio Pharma Announces $500 Million Stock Repurchase Program

BridgeBio Pharma ( (BBIO) ) just unveiled an announcement.

BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180.6 million in U.S. Attruby sales, alongside expanding real-world evidence showing significant mortality and quality-of-life benefits versus existing therapies, and bolstered its balance sheet to $940.2 million in cash and marketable securities as of March 31, 2026. On May 6, 2026, the board approved a stock repurchase program of up to $500 million of outstanding common shares, while the company advanced its rare-disease pipeline with an FDA NDA submission for BBP-418 in LGMD2I/R9, positive Phase 3 data and planned 2026 NDA filings for encaleret and infigratinib, and preparations for multiple potential U.S. launches between late 2026 and 2027, signaling confidence in long-term growth and shareholder value.

BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180.6 million in U.S. Attruby sales, alongside expanding real-world evidence showing significant mortality and quality-of-life benefits versus existing therapies, and bolstered its balance sheet to $940.2 million in cash and marketable securities as of March 31, 2026. On May 6, 2026, the board approved a stock repurchase program of up to $500 million of outstanding common shares, while the company advanced its rare-disease pipeline with an FDA NDA submission for BBP-418 in LGMD2I/R9, positive Phase 3 data and planned 2026 NDA filings for encaleret and infigratinib, and preparations for multiple potential U.S. launches between late 2026 and 2027, signaling confidence in long-term growth and shareholder value.

The most recent analyst rating on (BBIO) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

Spark’s Take on BBIO Stock

According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.

The score is held back primarily by weak current financials (large losses, heavy cash burn, and negative equity). Offsetting this, the latest earnings update and pipeline/commercial progress point to improving fundamentals over time, while technicals are neutral and valuation remains challenging due to ongoing losses and no dividend.

To see Spark’s full report on BBIO stock, click here.

More about BridgeBio Pharma

BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company focused on developing and marketing medicines for genetic conditions. Its lead product, Attruby (acoramidis), a near-complete transthyretin stabilizer for transthyretin amyloid cardiomyopathy, is driving strong U.S. revenue growth, while the company advances late-stage programs in rare diseases such as LGMD2I/R9, ADH1, achondroplasia, and hypochondroplasia, with a growing global footprint including recent approval in Brazil.

Average Trading Volume: 2,571,123

Technical Sentiment Signal: Buy

Current Market Cap: $13.33B

Learn more about BBIO stock on TipRanks’ Stock Analysis page.